The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | The future of ADCs in treating multiple myeloma
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses the emerging role of antibody-drug conjugates (ADCs) for multiple myeloma. Belantamab mafodotin (belamaf) remains the only ADC indicated for multiple myeloma and whilst it is currently only used as a monotherapy, findings from the Phase I/II DREAMM-6 trial (NCT03544281) demonstrated promising results in patients receiving bortezomib and dexamethasone with belamaf. The Phase III DREAMM-7 (NCT04246047) and DREAMM-8 (NCT04484623) trials will additionally assess belamaf with existing combination therapies. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
